ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Jefferies Financial Group upped their Q1 2021 earnings estimates for ACADIA Pharmaceuticals in a research report issued on Tuesday, April 6th. Jefferies Financial Group analyst C. Howerton now forecasts that the biopharmaceutical company will post earnings of ($0.53) per share for the quarter, up from their prior forecast of ($0.65). Jefferies Financial Group has a “Hold” rating and a $21.00 price objective on the stock. Jefferies Financial Group also issued estimates for ACADIA Pharmaceuticals’ Q2 2021 earnings at ($0.40) EPS, Q3 2021 earnings at ($0.32) EPS, Q4 2021 earnings at ($0.29) EPS, FY2021 earnings at ($1.54) EPS, FY2022 earnings at ($1.08) EPS, FY2023 earnings at ($1.36) EPS, FY2024 earnings at ($0.93) EPS and FY2025 earnings at $1.07 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Tuesday, February 23rd. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.05. The company had revenue of $121.01 million for the quarter, compared to analyst estimates of $122.87 million. ACADIA Pharmaceuticals had a negative return on equity of 40.35% and a negative net margin of 63.92%.

Other research analysts have also issued reports about the company. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell reiterated a “neutral” rating and issued a $35.00 target price (down previously from $66.00) on shares of ACADIA Pharmaceuticals in a report on Monday, March 15th. Canaccord Genuity lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price target for the company from $40.00 to $26.00 in a report on Tuesday. The Goldman Sachs Group lowered ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $73.00 to $25.00 in a research note on Monday. Guggenheim reiterated a “neutral” rating on shares of ACADIA Pharmaceuticals in a research note on Monday, March 15th. Finally, Cantor Fitzgerald upped their price target on shares of ACADIA Pharmaceuticals from $33.00 to $45.00 and gave the company an “overweight” rating in a report on Tuesday. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $33.78.

Shares of ACAD opened at $21.23 on Thursday. The firm has a market cap of $3.40 billion, a PE ratio of -12.34 and a beta of 1.44. The company’s fifty day moving average is $35.76 and its two-hundred day moving average is $46.24. ACADIA Pharmaceuticals has a fifty-two week low of $20.36 and a fifty-two week high of $58.72.

In other ACADIA Pharmaceuticals news, CEO Stephen Davis sold 14,195 shares of the stock in a transaction on Thursday, February 4th. The stock was sold at an average price of $50.61, for a total transaction of $718,408.95. Following the completion of the transaction, the chief executive officer now directly owns 43,059 shares of the company’s stock, valued at approximately $2,179,215.99. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Austin D. Kim sold 2,107 shares of the business’s stock in a transaction on Thursday, February 4th. The stock was sold at an average price of $50.61, for a total value of $106,635.27. Following the completion of the sale, the executive vice president now directly owns 12,018 shares in the company, valued at approximately $608,230.98. The disclosure for this sale can be found here. Insiders have sold a total of 57,215 shares of company stock worth $3,035,800 over the last 90 days. 27.70% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the stock. Baillie Gifford & Co. purchased a new position in ACADIA Pharmaceuticals in the 4th quarter worth about $28,000. Retirement Group LLC acquired a new position in shares of ACADIA Pharmaceuticals in the fourth quarter worth about $28,000. Capstone Triton Financial Group LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at approximately $30,000. Charter Oak Capital Management LLC purchased a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter valued at approximately $33,000. Finally, Perigon Wealth Management LLC acquired a new position in ACADIA Pharmaceuticals in the 4th quarter worth approximately $86,000. Institutional investors and hedge funds own 93.54% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia.

Further Reading: Does a trade war provide a risk to the global economy?

Earnings History and Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.